Pharma Mar (BME:PHM) Valuation Check After New Globant AI Partnership In Cancer Drug Discovery

Pharma Mar (BME:PHM) has drawn fresh attention after partnering with Globant to deploy a multi agent AI platform designed to support faster, more accurate cancer drug discovery across its research and development operations.

See our latest analysis for Pharma Mar.

The latest €86.45 share price comes after a 15.81% 90 day share price return and a 7.73% 30 day share price return. The 3 year total shareholder return of 108.30% contrasts with a 6.47% decline over five years, suggesting momentum has recently improved despite a softer 7.52% total shareholder return over the past year.

If Pharma Mar’s push into AI driven oncology research has your attention, it could be a good moment to see what else is happening across 120 healthcare AI stocks

With Pharma Mar trading at €86.45, sitting at a very large 55% discount to one intrinsic value estimate and around 20% below analyst targets, the key question is whether the current price represents an attractive valuation or if it already reflects expectations about future growth.

Price-to-Earnings of 20x: Is it justified?

On a P/E of 20x and a last close of €86.45, Pharma Mar screens as more expensive than the broader European biotech group but cheaper than its closer peer set.

The P/E multiple captures how much investors are paying today for each euro of current earnings. This is particularly relevant for a profitable, research heavy oncology business like Pharma Mar that is already generating €74.99m of net income on €221.39m of revenue.

Compared with the European Biotechs industry average of 16.3x, the 20x P/E trades at a premium. This indicates the market is placing a higher price on Pharma Mar’s earnings than the sector average. At the same time, the P/E remains below the peer average of 29.6x and below an estimated fair P/E of 34x that the market could move towards if current expectations hold.

Explore the SWS fair ratio for Pharma Mar

Result: Price-to-Earnings of 20x (ABOUT RIGHT)

However, you still need to weigh execution risk around AI integration and the possibility that key oncology trials or approvals do not progress as hoped.

Find out about the key risks to this Pharma Mar narrative.

Another View: Cash Flows Paint a Different Picture

While a 20x P/E suggests Pharma Mar is roughly in line with peers, the SWS DCF model points to something quite different. At €86.45, the shares sit around 55% below an estimated €190.58 future cash flow value, which implies the market may be pricing in a lot of execution risk.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pharma Mar for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 253 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

Given the mix of optimism around AI driven oncology and concern about execution risks, it makes sense to review the numbers yourself and decide quickly where you stand. To weigh the trade off between potential upside and the issues investors are watching, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Pharma Mar has sharpened your focus, do not stop here. The next opportunity you are looking for might sit just a few clicks away in the wider market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com